Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ZEALBullishCorporate Developmentsnews

High materiality7/10

Zealand Pharma reports week 39 buybacks; treasury stake reaches 6.72%

Sep 28, 2026, 12:57 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

A sizable ongoing buyback reduces outstanding shares and can lift EPS, often providing price support if execution remains steady and the market views capital return favorably.

AI summary

What happened, with direct paths to the underlying reporting

Zealand Pharma disclosed week-39 buyback transactions under its MAR-compliant program, with cumulative purchases of 3.94 million shares worth 1.176 billion DKK. The program permits up to 1.3 billion DKK for 7.15 million shares and runs through Oct 31, 2026, led by Danske Bank. After week 39, treasury stock stands at 4.81 million shares (6.72% of capital).

Zealand Pharma reports week 39 share buybacks under MAR; cumulative purchases reach 3.94M shares.
Program cap is up to DKK 1.3B for 7,152,557 shares; ends Oct 31, 2026.
Treasury shares total 4,810,842, about 6.72% of share capital.
Week 39 transactions: 315,000 shares; value 87,167,650 DKK; total shares 71,610,005.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Zealand Pharma reports week 39 buybacks; treasury stake reaches 6.72%

Zealand Phase 2 petrelintide data strengthens obesity therapy outlook

Roche takes big step in weight-loss field with $5.3 billion deal. Novo Nordisk shares fall. - MarketWatch

Zealand Pharma Shares Jump 17% After Positive Trial Results For Ozempic Competitor